Drugs in MeSH Category Anesthetics, Intravenous

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apothecon	MIDAZOLAM HYDROCHLORIDE	midazolam hydrochloride	INJECTABLE;INJECTION	075620-002	Nov 1, 2000		DISCN	No	No
Avadel Cns	LUMRYZ	sodium oxybate	FOR SUSPENSION, EXTENDED RELEASE;ORAL	214755-003	May 1, 2023		RX	Yes	No			Y
Btcp Pharma	SUBSYS	fentanyl	SPRAY;SUBLINGUAL	202788-001	Jan 4, 2012		DISCN	Yes	No
Hikma	DIAZEPAM	diazepam	SOLUTION;ORAL	070928-001	Apr 3, 1987	AA	RX	No	Yes
Hospira	DIAZEPAM	diazepam	INJECTABLE;INJECTION	071583-001	Oct 13, 1987	AP	RX	No	Yes
Warner Chilcott	DIAZEPAM	diazepam	INJECTABLE;INJECTION	071614-001	Oct 22, 1987		DISCN	No	No

Anesthetics, Intravenous Market Analysis and Financial Projection

The U.S. intravenous (IV) anesthesia drugs market is characterized by robust growth driven by technological innovation, regulatory support, and strategic industry developments. Valued at $1.72 billion in 2024, it is projected to expand at a 2.82% CAGR through 2030, with the IV segment dominating revenue share (63–65%) and leading growth (3.03–4.6% CAGR) due to its rapid onset, precision, and cost-effectiveness[1][3][5][8]. Below, we analyze market dynamics and patent trends shaping this sector.

---

Market Dynamics

Key Growth Drivers

1. Technological Advancements:

   • Target-controlled infusion (TCI) systems and automated pumps enhance dosing accuracy, reducing complications[2][10][13].
   • Ultra-short-acting agents like remifentanil and propofol derivatives (e.g., LK-396) optimize recovery times and safety[1][6][14].
   • New formulations such as ZYNRELEFTM (bupivacaine/meloxicam) prolong pain relief post-surgery[1][14].

2. Regulatory Approvals:

   • The FDA’s stringent oversight ensures safe drug launches. Recent approvals include Rocuronium Bromide (muscle relaxation) and Ropivacaine Hydrochloride (local anesthesia), driving market competitiveness[1][14].
   • Patent expirations (e.g., Lusedra in 2022) enable generics to enter, broadening accessibility[11].

3. Surgical Demand:

   • Rising knee/hip replacements and cancer surgeries necessitate reliable IV anesthesia[5].
   • Outpatient procedures favor propofol for its rapid recovery, capturing 25% market share[5][14].

Segment Insights

Segment	Market Share (2024)	Key Factors
Propofol	25.18%[5]	Rapid onset, cost-effectiveness, and outpatient suitability.
IV Delivery	63–65%[3][5][8]	Precision via TCI pumps, minimal aerosol risk (critical during COVID-19)[10].
Hospitals	67.22%[5]	Central hubs for complex surgeries, equipped with advanced monitoring.

---

Patent Landscape

Innovations in Drug Delivery Systems

Patent	Focus	Impact
US6186977B1[2]	Integrated IV anesthesia apparatus	Combines drug infusion with real-time patient monitoring (e.g., ECG, blood pressure).
US8038642B2[13]	Computer-controlled dosing	Uses pharmacokinetic models to adjust anesthesia depth dynamically.
US20100069438A1[12]	Propofol-opioid combinations	Streamlines induction/maintenance, enabling single-vial administration.

Emerging Drug Candidates

• LK-396: Water-soluble propofol prodrug with reduced toxicity[6].
• Remimazolam: Short-acting benzodiazepine derivative for rapid sedation[6][10].
• Ciprofol: Novel agent under study for balanced anesthesia[10].

---

Regulatory and Industry Trends

• Mergers & Acquisitions: Companies like Baxter and AbbVie expand portfolios via strategic launches (e.g., Ropivacaine Hydrochloride)[1][14].
• Environmental Focus: IV anesthesia’s lower carbon footprint vs. inhalational agents boosts adoption[3].
• Post-COVID Shifts: TIVA’s aerosol-free delivery remains preferred in NORA (non-operating room anesthesia) settings[10].

---

Future Outlook

The IV anesthesia market will likely see sustained growth through:

• Expanded use in ambulatory surgical centers (3.6% CAGR)[5].
• Development of dual-mechanism drugs (e.g., sedation + analgesia).
• Integration of AI-driven monitoring for personalized dosing[13][14].

As R&D focuses on safer formulations and delivery tech, the sector is poised to meet escalating demand for efficient, patient-tailored anesthesia solutions.

References

1. https://www.grandviewresearch.com/industry-analysis/us-general-anesthesia-drugs-market-report
2. https://patents.google.com/patent/US6186977B1/en
3. https://www.biospace.com/press-releases/general-anesthesia-drugs-market-size-to-reach-usd-8-791-million-by-2034
4. https://meshb.nlm.nih.gov/record/ui?ui=D018681
5. https://www.biospace.com/press-releases/u-s-general-anesthesia-drugs-market-size-to-hit-usd-2-56-billion-by-2033
6. https://www.protheragen.com/pdf-down/product-portfolio-intravenous-anesthetics/
7. https://en.wikipedia.org/wiki/List_of_MeSH_codes_(E03)
8. https://www.snsinsider.com/reports/anesthesia-drugs-market-4561
9. https://patents.justia.com/patents-by-us-classification/514/816
10. https://pmc.ncbi.nlm.nih.gov/articles/PMC10034929/
11. https://www.marketsandmarkets.com/Market-Reports/anesthesia-drugs-ketamine-market-713.html
12. https://patents.google.com/patent/US20100069438A1/en
13. https://patents.google.com/patent/US8038642B2/en
14. https://www.grandviewresearch.com/industry-analysis/general-anesthesia-drugs-market-report